Extensive survey of STAT6 expression in a large series of mesenchymal tumors

American Journal of Clinical Pathology

Volumn 143, Issue 5, 2015, Pages 672-682

  Demicco, Elizabeth G ^a   Harms, Paul W ^b   Patel, Rajiv M ^b   Smith, Steven C ^b   Ingram, Davis ^c   Torres, Keila ^c   Carskadon, Shannon L ^b   Camelo Piragua, Sandra ^b   McHugh, Jonathan B ^b   Siddiqui, Javed ^b   Palanisamy, Nallasivam ^b   Lucas, David R ^b   Lazar, Alexander J ^c   Wang, Wei Lien ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Immunohistochemistry; Sarcoma; Solitary fibrous tumor; STAT6

Indexed keywords

STAT6 PROTEIN; STAT6 PROTEIN, HUMAN; TUMOR MARKER;

ALVEOLAR SOFT PART SARCOMA; ARTICLE; DEDIFFERENTIATED LIPOSARCOMA; DESMOID TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MAJOR CLINICAL STUDY; MESENCHYMOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; TISSUE MICROARRAY; CELL NUCLEUS; CHILD; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SOFT TISSUE TUMOR; SOLITARY FIBROUS TUMOR;

BIOMARKERS, TUMOR; CELL NUCLEUS; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; SARCOMA; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS; SOLITARY FIBROUS TUMORS; STAT6 TRANSCRIPTION FACTOR; TISSUE ARRAY ANALYSIS;

EID: 84940749535     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPN25NJTOUNPNF     Document Type: Article

References (46)

1. Reich NC. STATs get their move on. JAKSTAT. 2013;2:e27080.
2. Hou J, Schindler U, Henzel WJ, et al. An interleukin-4-induced transcription factor: IL-4. Stat Sci. 1994;265:1701-1706.
3. Izuhara K, Heike T, Otsuka T, et al. Signal transduction pathway of interleukin-4 and interleukin-13 in human B cells derived from X-linked severe combined immunodeficiency patients. J Biol Chem. 1996;271:619-622.
4. Chen HC, Reich NC. Live cell imaging reveals continuous STAT6 nuclear trafficking. J Immunol. 2010;185:64-70.
5. Ostrand-Rosenberg S, Sinha P, Clements V, et al. Signal transducer and activator of transcription 6 (Stat6) and CD1: inhibitors of immunosurveillance against primary tumors and metastatic disease. Cancer Immunol Immunother. 2004;53:86-91.
6. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99:618-626.
7. Carey GB, Semenova E, Qi X, et al. IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contribution of the PI-3 kinase/AKT pathway. Cell Res. 2007;17:942-955.
8. Das S, Roth CP, Wasson LM, et al. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer. Prostate. 2007;67:1550-1564.
9. Xu SB, Liu XH, Li BH, et al. DNA methylation regulates constitutive expression of Stat6 regulatory genes SOCS-1 and SHP-1 in colon cancer cells. J Cancer Res Clin Oncol. 2009;135:1791-1798.
10. Wang CG, Ye YJ, Yuan J, et al. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis. World J Gastroenterol. 2010;16:2421-2427.
11. Das S, Shetty P, Valapala M, et al. Signal transducer and activator of transcription 6 (STAT6) is a novel interactor of annexin A2 in prostate cancer cells. Biochemistry. 2010;49:2216-2226.
12. Hosoyama T, Aslam MI, Abraham J, et al. IL-4R drives dedifferentiation, mitogenesis, and metastasis in rhabdomyosarcoma. Clin Cancer Res. 2011;17:2757-2766.
13. Frank DA. STAT6 in PMBL: pathogenic or passenger? Blood. 2009;114:1133-1134.
14. Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013;45:180-185.
15. Chmielecki J, Crago AM, Rosenberg M, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013;45:131-132.
16. Fletcher CDM, Bridge JA, Lee J-C. Extrapleural solitary fibrous tumor. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, et al, eds. World Health Organization of Tumors of Soft Tissue and Bone. Lyon, France: IARC Press; 2013:80-82.
17. Demicco EG, Park MS, Araujo DM, et al. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol. 2012;25:1298-1306.
18. Bhattacharyya S, Fang F, Tourtellotte W, et al. Egr-1: new conductor for the tissue repair orchestra directs harmony (regeneration) or cacophony (fibrosis). J Pathol. 2013;229:286-297.
19. Mohajeri A, Tayebwa J, Collin A, et al. Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer. 2013;52:873-886.
20. Barthelmess S, Geddert H, Boltze C, et al. Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features. Am J Pathol. 2014;184:1209-1218.
21. Schweizer L, Koelsche C, Sahm F, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013;125:651-658.
22. Doyle LA, Vivero M, Fletcher CD, et al. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2013;27:390-395.
23. Ni Z, Lou W, Lee SO, et al. Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma. J Urol. 2002;167:1859-1862.
24. Gooch JL, Christy B, Yee D. STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells. Neoplasia. 2002;4:324-331.
25. Zhang M, Zhou Y, Xie C, et al. STAT6 specific shRNA inhibits proliferation and induces apoptosis in colon cancer HT-29 cells. Cancer Lett. 2006;243:38-46.
26. Yoshida A, Tsuta K, Ohno M, et al. STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors. Am J Surg Pathol. 2014;38:552-559.
27. Koelsche C, Schweizer L, Renner M, et al. Nuclear relocation of STAT6 reliably predicts NAB2/STAT6 fusion for the diagnosis of solitary fibrous tumour. Histopathology. 2014;65:613-622.
28. Demicco EG, Boland GM, Brewer Savannah KJ, et al. Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value. Histopathology. 2015;66:627-638.
29. Lusby K, Savannah KB, Demicco EG, et al. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience. Ann Surg Oncol. 2013;20:2364-2372.
30. Lahat G, Tuvin D, Wei C, et al. Molecular prognosticators of complex karyotype soft tissue sarcoma outcome: a tissue microarray-based study. Ann Oncol. 2010;21:1112-1120.
31. Lahat G, Zhang P, Zhu QS, et al. The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study. Histopathology. 2011;59:556-561.
32. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518-1527.
33. Colombo C, Foo WC, Whiting D, et al. FAP-related desmoid tumors: a series of 44 patients evaluated in a cancer referral center. Histol Histopathol. 2012;27:641-649.
34. Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg. 2009;249:1014-1022.
35. Lahat G, Dhuka AR, Hallevi H, et al. Angiosarcoma: clinical and molecular insights. Ann Surg. 2010;251:1098-1106.
36. Lazar AJ, Lahat G, Myers SE, et al. Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray. Histopathology. 2009;55:750-755.
37. Sakharpe A, Lahat G, Gulamhusein T, et al. Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model. Oncologist. 2011;16:512-522.
38. Demicco EG, Torres KE, Ghadimi MP, et al. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol. 2012;25:212-221.
39. Ghadimi MP, Liu P, Peng T, et al. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer. 2011;117:5359-5369.
40. Zhang P, Bill K, Liu J, et al. MiR-155 is a liposarcoma oncogene that targets casein kinase-1alpha and enhances beta-catenin signaling. Cancer Res. 2012;72:1751-1762.
41. Doyle LA, Tao D, Marino-Enriquez A. STAT6 is amplified in a subset of dedifferentiated liposarcoma. Mod Pathol. 2014;27:1231-1237.
42. Agaimy A, Barthelmess S, Geddert H, et al. Phenotypic and molecular distinctness of sinonasal hemangiopericytoma compared to solitary fibrous tumor of the sinonasal tract. Histopathology. 2014;65:667-673.
43. Bode-Lesniewska B, Zhao J, Speel EJ, et al. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery. Virchows Arch. 2001;438:57-65.
44. Neuville A, Collin F, Bruneval P, et al. Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysis of 100 primary cardiac sarcomas. Am J Surg Pathol. 2014;38:461-469.
45. Harp JB, Franklin D, Vanderpuije AA, et al. Differential expression of signal transducers and activators of transcription during human adipogenesis. Biochem Biophys Res Commun. 2001;281:907-912.
46. Barron L, Wynn TA. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am J Physiol Gastrointest Liver Physiol. 2011;300:G723-G728.